Roche personalized cancer drug Rozlytrek nabs first approval

June 18, 2019

Roche’s Rozlytrek, also known as entrectinib, has won its first global approval in Japan. The personalized cancer medicine targets patients who must be identified via genetic profiling.

The med targets people with NTRK fusion-positive solid tumors, including breast, colorectal, neuroendocrine, lung and pancreatic cancers.

NTRK fusions are a rare genetic anomaly that drive growth in a range of tumors.

Bayer’s Vitrakvi has previously received approval in the United States for solid tumors that test positive for NTRK genes.

Read the Reuters report.